nach oben

American Journal of Clinical Dermatology

Erschienen in:

19.04.2021 | Review Article

50 Years of Topical Retinoids for Acne: Evolution of Treatment

verfasst von: Hilary Baldwin, Guy Webster, Linda Stein Gold, Valerie Callender, Fran E. Cook-Bolden, Eric Guenin

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Since the US Food and Drug Administration (FDA) approved tretinoin in 1971, retinoids alone or combined with other agents have become the mainstay of acne treatment. Retinoids act through binding to retinoic acid receptors, altering expression levels of hundreds of cellular proteins affecting multiple pathways involved in acne pathogenesis. Retinoids have evolved from first-generation agents, such as tretinoin, through chemical modifications resulting in a second generation (etretinate and acitretin for psoriasis), a third generation (adapalene and tazarotene) and, most recently, a fourth (trifarotene). For all topical retinoids, local irritation has been associated with poor tolerability and suboptimal adherence. Efforts to improve tolerability have utilized novel delivery systems and/or novel agents. This qualitative literature review summarizes the evolution of the four topical single-agent retinoids available for the treatment of acne in the US today and their various formulations, presenting the rationale behind their development and data from key studies.

US Food and Drug Administration. Drugs@FDA-Approved Drugs. 2020. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016921. Accessed 28 Apr 2020.

Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293–304.PubMedPubMedCentralCrossRef

Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.PubMedCrossRef

Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–50.PubMedCrossRef

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–73 e33.

Kligman AM. The treatment of acne with topical retinoids: one man’s opinions. J Am Acad Dermatol. 1997;36(6 Pt 2):S92–5.PubMedCrossRef

Tan J, Tanghetti E, Baldwin H, Stein Gold L, Lain E. The role of topical retinoids in prevention and treatment of atrophic acne scarring: understanding the importance of early effective treatment. J Drugs Dermatol. 2019;18(3):255–60.PubMed

Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.PubMedPubMedCentral

Riahi RR, Bush AE, Cohen PR. Topical retinoids: therapeutic mechanisms in the treatment of photodamaged skin. Am J Clin Dermatol. 2016;17(3):265–76.PubMedCrossRef

10.

Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther (Heidelb). 2017;7(3):305–18.PubMedPubMedCentralCrossRef

11.

Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;1:15029.PubMedCrossRef

12.

Boswell CB. Skincare science: update on topical retinoids. Aesthet Surg J. 2006;26(2):233–9.PubMedCrossRef

13.

Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther. 2005;27(2):216–24.PubMedCrossRef

14.

Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International union of pharmacology. LX. Retinoic acid receptors. Pharmacol Rev. 2006;58(4):712–25.PubMedCrossRef

15.

Elder JT, Fisher GJ, Zhang QY, Eisen D, Krust A, Kastner P, et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol. 1991;96(4):425–33.PubMedCrossRef

16.

Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J. 1996;10(9):1002–13.PubMedCrossRef

17.

Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28(8):684–96.PubMedCrossRef

18.

Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2 Pt 3):S17–24.PubMedCrossRef

19.

Dreno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29(Suppl 4):3–11.PubMedCrossRef

20.

Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469–76.PubMedCrossRef

21.

Bershad S. Developments in topical retinoid therapy for acne. Semin Cutan Med Surg. 2001;20(3):154–61.PubMedCrossRef

22.

Rigopoulos D, Ioannides D, Kalogeromitros D, Katsambas AD. Comparison of topical retinoids in the treatment of acne. Clin Dermatol. 2004;22(5):408–11.PubMedCrossRef

23.

Chen S, Ostrowski J, Whiting G, Roalsvig T, Hammer L, Currier SJ, et al. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models. J Invest Dermatol. 1995;104(5):779–83.PubMedCrossRef

24.

Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 1998;39(4 Pt 2):S124–8.PubMedCrossRef

25.

Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol. 1987;16(2 Pt 1):267–91.PubMedCrossRef

26.

Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53(5):525–38.PubMedCrossRef

27.

US Food and Drug Administration. NDA-20-338. 1996. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020338Orig1s000rev.pdf. Accessed 29 Apr 2020.

28.

Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6 Pt 2):S96–103.PubMedCrossRef

29.

Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol. 1997;36(6 Pt 2):S119–25.PubMedCrossRef

30.

Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997;36(3 Pt 2):S37-46.PubMedCrossRef

31.

Saurat JH, Sorg O. Topical natural retinoids. The “proligand-non-ligand” concept. Dermatology. 1999;199(Suppl 1):1–2.PubMedCrossRef

32.

Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48–56.

33.

Tazorac^®[package insert]. Irvine: Allergan, Inc.; 1997.

34.

Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41(6):927–30.PubMedCrossRef

35.

Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4–9.

36.

Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4–11.

37.

Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4(2):153–8.PubMed

38.

Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345–65.PubMedCrossRef

39.

Tolaymat L, Zito PM. Adapalene. [Updated 2020 Sep 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021-Jan. https://www.ncbi.nlm.nih.gov/books/NBK482509/

40.

Latter G, Grice JE, Mohammed Y, Roberts MS, Benson HAE. Targeted topical delivery of retinoids in the management of acne vulgaris: current formulations and novel delivery systems. Pharmaceutics. 2019;11(10):490.

41.

The medical letter on drugs and therapeutics. Trifarotene (Aklief^®)—A new topical retinoid for acne. JAMA. 2020;323(13):1310–1.CrossRef

42.

Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.PubMedCrossRef

43.

Aklief^® [package insert]. Galderma Laboratories L, Switzerland; 2019.

44.

Culp L, Moradi Tuchayi S, Alinia H, Feldman SR. Tolerability of topical retinoids: are there clinically meaningful differences among topical retinoids? J Cutan Med Surg. 2015;19(6):530–8.PubMedCrossRef

45.

Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18(5):524–6.

46.

Feldman SR, Werner CP, Alio Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013;12(4):438–46.

47.

Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641–51.PubMed

48.

Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369–81.PubMedCrossRef

49.

Pomerantz H, Weinstock MA, VATTC. Predictors of local adverse effects caused by topical tretinoin cream 0.1% in the Veterans Affairs Topical Tretinoin Chemoprevention trial. Br J Dermatol. 2014;171(3):642–5.

50.

Dreno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448–56.PubMedCrossRef

51.

Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211–6.PubMedCrossRef

52.

Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21.PubMedPubMedCentralCrossRef

53.

Hoffman LK, Bhatia N, Zeichner J, Kircik LH. Topical vehicle formulations in the treatment of acne. J Drugs Dermatol. 2018;17(6):S6–10.PubMed

54.

Del Rosso JQ, Kircik LH, Zeichner J, Stein GL. The clinical relevance and therapeutic benefit of established active ingredients incorporated into advanced foam vehicles: vehicle characteristics can influence and improve patient outcomes. J Drugs Dermatol. 2019;18(2s):S100–7.PubMed

55.

Anderson KL, Dothard EH, Huang KE, Feldman SR. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623–6.PubMedCrossRef

56.

Tan X, Al-Dabagh A, Davis SA, Lin HC, Balkrishnan R, Chang J, et al. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris. Am J Clin Dermatol. 2013;14(3):243–51.PubMedCrossRef

57.

Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.PubMedCrossRef

58.

Dikicier BS. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987–92.

59.

Veraldi S, Barbareschi M, Benardon S, Schianchi R. Short contact therapy of acne with tretinoin. J Dermatolog Treat. 2013;24(5):374–6.PubMedCrossRef

60.

Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis. 2001;67(6 Suppl):10–16.

61.

Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 Pt 3):S67–73.PubMedCrossRef

62.

Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):S148–54.PubMed

63.

Kaity S, Maiti S, Ghosh AK, Pal D, Ghosh A, Banerjee S. Microsponges: a novel strategy for drug delivery system. J Adv Pharm Technol Res. 2010;1(3):283–90.PubMedPubMedCentralCrossRef

64.

Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575–88.PubMedCrossRef

65.

Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J Drugs Dermatol. 2008;7(8 Suppl):S2–8.PubMed

66.

Kircik LH. The microsponge delivery system reduces facial oiliness and shine during acne therapy. J Drugs Dermatol. 2013;12(11):1268–70.PubMed

67.

Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38(4):S17–23.

68.

Torok HM, Pillai R. Safety and efficacy of micronized tretinoin gel (0.05%) in treating adolescent acne. J Drugs Dermatol. 2011;10(6):647–52.

69.

Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084–91.

70.

Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019:1–8.

71.

Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.

72.

Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70–7.

73.

Data on file, Bausch Health Americas, Inc. Studies V01-121A-301 and V01-121A-302.

74.

Data on file, Bausch Health Americas, Inc. Studies V01-123A-301 and V01-123A-302.

75.

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J et al. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2010;9(6):639–46.

Titel: 50 Years of Topical Retinoids for Acne: Evolution of Treatment
verfasst von: Hilary Baldwin
Guy Webster
Linda Stein Gold
Valerie Callender
Fran E. Cook-Bolden
Eric Guenin
Publikationsdatum: 19.04.2021
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 3/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-021-00594-8

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

HLA-Cw1 and Psoriasis

Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

Eczematous Drug Eruptions

Dermatitis Herpetiformis: An Update on Diagnosis and Management

The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma